within Pharmacolibrary.Drugs.ATC.L;

model L01DB09
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.05,
    Cl             = 1.3099999999999998,
    adminDuration  = 600,
    adminMass      = 0.8,
    adminCount     = 1,
    Vd             = 0.325,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Valrubicin is a semisynthetic anthracycline derivative used as an antineoplastic agent, primarily for the intravesical treatment of Bacillus Calmette-Guerin (BCG)-refractory carcinoma in situ of the urinary bladder. It is approved for this indication and is not recommended for systemic administration.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic data are reported for adults with BCG-refractory carcinoma in situ of the bladder following intravesical administration.</p><h4>References</h4><ol><li><p>Onrust, SV, &amp; Lamb, HM (1999). Valrubicin. <i>Drugs &amp; aging</i> 15(1) 69–76. DOI:<a href=&quot;https://doi.org/10.2165/00002512-199915010-00006&quot;>10.2165/00002512-199915010-00006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10459733/&quot;>https://pubmed.ncbi.nlm.nih.gov/10459733</a></p></li><li><p>Porten, SP, et al., &amp; Greene, KL (2015). Intravesical chemotherapy in non-muscle-invasive bladder cancer. <i>Indian journal of urology : IJU : journal of the Urological Society of India</i> 31(4) 297–303. DOI:<a href=&quot;https://doi.org/10.4103/0970-1591.166446&quot;>10.4103/0970-1591.166446</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26604440/&quot;>https://pubmed.ncbi.nlm.nih.gov/26604440</a></p></li><li><p>Patterson, AL, et al., &amp; Gulfo, J (2000). Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer. <i>Urology</i> 56(2) 232–235. DOI:<a href=&quot;https://doi.org/10.1016/s0090-4295(00)00654-3&quot;>10.1016/s0090-4295(00)00654-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10925084/&quot;>https://pubmed.ncbi.nlm.nih.gov/10925084</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01DB09;
